Related Experiment Video
Updated: Apr 16, 2026

Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits
Published on: February 28, 2025
N-acetylcysteine effectively diminished meconium-induced oxidative stress in adult rabbits
1Department of Physiology, Comenius University in Bratislava, Jessenius School of Medicine in Martin, Martin, Slovakia. mokra@jfmed.uniba.sk.
Abstract:
Since inflammation and oxidative stress are fundamental in the pathophysiology of neonatal meconium aspiration syndrome (MAS), various anti-inflammatory drugs have been used in experimental and clinical studies on MAS. This pilot study evaluated therapeutic potential of N-acetylcysteine in modulation of meconium-induced inflammation and oxidative lung injury. Oxygen-ventilated adult rabbits were intratracheally given 4 ml/kg of meconium (25 mg/ml) or saline (Sal, n = 6). Thirty minutes later, meconium-instilled animals were treated with intravenous N-acetylcysteine (10 mg/kg, Mec + NAC, n=6) or were non-treated (Mec, n = 6). All animals were oxygen-ventilated for additional 5 hours. Total and differential blood leukocyte counts were determined at baseline, and at 1, 3 and 5 h of the treatment. After sacrificing animals, left lung was saline-lavaged and total and differential cell counts in the bronchoalveolar lavage fluid were determined. Right lung was used for biochemical analyses and for estimation of wet-dry weight ratio. In lung tissue homogenate, thiobarbituric acid-reactive substances (TBARS), dityrosine, lysine-lipid peroxidation (LPO) products, and total antioxidant status (TAS) were detected. In isolated lung mitochondria, TBARS, dityrosine, lysine-LPO products, thiol group content, conjugated dienes, and activity of cytochrome c oxidase were estimated. To evaluate systemic effects of meconium instillation and NAC treatment, TBARS and TAS were determined also in plasma. To evaluate participation of eosinophils in the meconium-induced inflammation, eosinophil cationic protein (ECP) was detected in plasma and lung homogenate. Meconium instillation increased oxidation markers and ECP in the lung and decreased TAS (all P<0.05). NAC treatment reduced ECP and oxidation markers (all P<0.05, except of dityrosine in homogenate and conjugated dienes in mitochondria) and prevented a decrease in TAS (P<0.01) in lung homogenate compared to Mec group. In plasma, NAC decreased TBARS (P<0.001) and ECP, and increased TAS (both P<0.05) compared to Mec group. Concluding, N-acetylcysteine diminished meconium-induced inflammation and oxidative lung injury.
Insights
N-acetylcysteine (NAC) reduced inflammation and oxidative lung injury in a rabbit model of meconium aspiration syndrome (MAS). This study shows NAC
Area of Science:
- Neonatal respiratory medicine
- Pulmonary toxicology
- Pharmacology
Background:
- Neonatal meconium aspiration syndrome (MAS) involves inflammation and oxidative stress.
- Existing treatments for MAS have limitations.
- N-acetylcysteine (NAC) is explored for its anti-inflammatory and antioxidant properties.
Purpose of the Study:
- To evaluate the therapeutic potential of N-acetylcysteine (NAC) in mitigating meconium-induced inflammation and oxidative lung injury.
- To assess the impact of NAC on biochemical markers of oxidative stress and inflammation in a rabbit model of MAS.
Main Methods:
- Adult rabbits were intratracheally instilled with meconium or saline.
- Meconium-instilled rabbits received intravenous N-acetylcysteine (NAC) or were untreated.
- Lung and plasma samples were analyzed for oxidative stress markers (TBARS, dityrosine, LPO), antioxidant status (TAS), and eosinophil cationic protein (ECP).
Main Results:
- Meconium instillation increased oxidative stress markers and ECP in the lung and plasma, while decreasing total antioxidant status (TAS).
- NAC treatment significantly reduced ECP and oxidative stress markers in both lung and plasma.
- NAC administration prevented the decrease in TAS in lung homogenate and increased TAS in plasma.
Conclusions:
- N-acetylcysteine (NAC) effectively diminishes meconium-induced inflammation and oxidative lung injury.
- NAC demonstrates therapeutic potential for managing MAS by reducing oxidative stress and inflammatory responses.
- Further clinical investigation of NAC for MAS treatment is warranted.

